Everolimus drug‐eluting stent performance in patients with long coronary lesions: The multicenter Longprime registry

Fernández, José Francisco Díaz; Freire, Santiago Jesús Camacho; Guerrero, José Carlos; Delarche, Nicolas; Bretelle, Christophe; Gil, Javier Zueco; Palop, Ramón Lopéz; Blanco, Bruno García del; Tello, Vicente Mainar; Albert, Franck

doi:10.1002/ccd.27657

Cited by 8 publications

(5 citation statements)

References 32 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kang et al previously compared the 12-month outcomes of three randomized clinical trials of the LONG-DES (LONG-DES III, IV, and V trials) in percutaneous treatment of LONG native coronary lesions with DES. The comparison of their findings with those of our study is shown in Table 5 [23,[26][27][28][29][30][31][32]. Our MACE outcomes are superior to all studies compared by Kang et al [23].…”

Section: Discussionsupporting

confidence: 52%

Long-Term Safety and Performance of BioMime™ Morph Sirolimus-Eluting Coronary Stent System for Very Long Coronary Lesions

Patted

2024

Cardiol Res

View full text Add to dashboard Cite

Background The use of multiple overlapping stents for long lesions in tapered coronary arteries has been associated with poor outcomes. This study was conducted to evaluate the 3-year safety and performance of the BioMime™ Morph sirolimus-eluting stent (SES) in very long (length 30 to ≤ 56 mm) coronary lesions in native coronary arteries with a reference vessel diameter of 2.25 to 3.50 mm. Methods This was a prospective, single-center, observational, real-world, post-marketing surveillance study. Eligible patients were implanted with BioMime™ Morph SES. Patients were followed up at 6, 12, 24, and 36 months. Results A total of 88 patients were enrolled in the study. The mean age was 58.72 ± 10.10 years and 82.95% were male. Most patients had angina (81.82%) and ischemic heart disease (78.41%), and there was a high prevalence of comorbidities like diabetes mellitus (59.09%), and hypertension (54.55%). A total of 92 long coronary de novo lesions were treated with BioMime™ Morph SES with an average stent length of 45.54 ± 10.20 mm. Device and procedural success rates were 100%. One patient died at 30 days and one case of myocardial infarction was recorded. The cumulative rates of major adverse cardiovascular events (MACEs) at 6, 12, 24, and 36 months were 3.41%, 6.82%, 7.95%, and 7.95%, respectively. There were no cases of stent thrombosis (ST), ischemia-driven target vessel revascularization, or ischemia-driven target lesion revascularization until 36 months of follow-up. Conclusion BioMime™ Morph SES showed favorable outcomes up to 3 years in treating very long coronary lesions in native coronary arteries, as demonstrated by an acceptable rate of MACEs and absence of ST, based on clinical outcomes up to 3 years.

show abstract

Section: Discussionsupporting

confidence: 52%

Long-Term Safety and Performance of BioMime™ Morph Sirolimus-Eluting Coronary Stent System for Very Long Coronary Lesions

Patted

2024

Cardiol Res

View full text Add to dashboard Cite

show abstract

“…In this study, there were also many diffuse lesions, and the total length of devices in RA/DES group reached 52.16 ± 20.76 mm. Research shows that the implantation of lengthy stents may hinder the stented segment's ability to regain vasomotion, encourage neoatherosclerosis, and restrict access to revascularization [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical research of drug-coated balloon after rotational atherectomy for severe coronary artery calcification

Dong

Shan

Gong

et al. 2023

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Current research results show that drug-coated balloons (DCB) have unique advantages in the treatment of in-stent restenosis, small vessel disease, bifurcation lesions, and de novo lesions, but the data regarding rotational atherectomy (RA) followed by DCB treatment in calcified lesions, especially severe coronary artery calcification (CAC), are limited. Methods A retrospective study was conducted on 318 individuals with severe CAC who underwent RA-assisted PCI at the First Affiliated Hospital of Zhengzhou University from May 2018 to July 2021. Among them, 57 patients (RA/DCB group) were treated with DCB, and 261 patients (RA/DES group) were treated with drug-eluting stents (DES). The two groups' clinical baseline data, lesion characteristics, intraoperative complications, in-hospital adverse events, and major adverse cardiovascular and cerebrovascular events (MACCE) were compared throughout the follow-up period. Results The baseline clinical data, intraoperative complications, and in-hospital adverse events were not significantly different between the two groups. The anatomical categories in the RA/DES group were more complex and included left main coronary disease, bifurcation disease, and multivessel disease. Although target lesion revascularization (13.79% vs. 7.02%) and MACCE (18.77% vs. 12.28%) occurred more frequently in the RA/DES group than in the RA/DCB group, there was no statistically significant difference (p > 0.05). Multivariate Cox regression analysis showed that bifurcation lesions (HR 2.284, 95% CI 1.063–4.908, p = 0.034), total length of DCB/DES (HR 1.023, 95% CI 1.005–1.047, p = 0.014) and SYNTAX score (HR 1.047, 95% CI 1.013–1.082, p = 0.006) were independent risk factors for MACCE during the follow-up period. Conclusion Drug-coated balloon treatment after rotational atherectomy appears safe and effective in selected severe coronary artery calcification.

show abstract

“…Astonishingly the postdilation rate was between 52 and 66% [21–23]. Fernandes et al analyzed a real world population with long coronary lesions after implantation of an everolimus-eluting stent [7]. The MACE and ST rates at 12, and 24-months follow-up were 2.1, 5.4% (MACE) and 0.7, 1.5% (ST) [7].…”

Section: Discussionmentioning

confidence: 99%

“…Fernandes et al analyzed a real world population with long coronary lesions after implantation of an everolimus-eluting stent [7]. The MACE and ST rates at 12, and 24-months follow-up were 2.1, 5.4% (MACE) and 0.7, 1.5% (ST) [7]. The scaffold thrombosis rate in our study was 1.4, 0.0% and for DOCE 8.9, 9.9%, after 12 and 24-month follow-up.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies showed that even in very complex lesions like chronic total occlusions the implantation of Absorb BVS with the PSP-technique is associated with a low risk of thrombotic events and good clinical outcomes [5, 6]. From DES-trials it is known that patients with short coronary lesions have lower MACE-rates and a better outcome compared to DES in long lesions [7–10]. In addition, it is well known that BVS with Absorb is associated with a worse outcome compared to DES.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical results of bioresorbable drug-eluting scaffolds in short and long coronary artery lesions using the PSP technique

Reichart

Wöhrle

Markovic

et al. 2019

BMC Cardiovasc Disord

View full text Add to dashboard Cite

BackgroundData on bioresorbable vascular scaffolds (BVS) for the treatment of long lesions are limited. We studied the use of BVS-Absorb in routine clinical practice and compared the outcome of long lesions with short lesions. Implantation of drug-eluting scaffolds without PSP-technique (predilation, proper sizing and postdilation) is associated with an increased thrombotic risk. We compared the long-term outcome up to 36 months of patients with short (< 20 mm) and long (≥20 mm) coronary artery lesions after implantation of bioresorbable vascular scaffolds (BVS) via PSP-technique.MethodsThree hundred twenty-six patients with 424 lesions were enrolled in this prospective study and underwent percutaneous coronary intervention with the Absorb BVS. Clinical follow-up was scheduled after 12, 24 and 36 months. In all lesions the PSP-technique was used. The device oriented composite endpoint (DOCE) was defined as cardiac death, myocardial infarction (MI) not clearly related to a non-target vessel and target lesion revascularization (TLR).ResultsKaplan-Meier estimates for DOCE after 12 months were 2.63% for short lesions and 8.09% for long lesions (p = 0.0131), 5.51% vs. 11.35% (p = 0.0503) after 24 months and 8.00% vs. 18.00% (p = 0.0264) after 36 months of clinical follow-up. Kaplan-Meier estimates for TLR after 12 months were 1.46% for short and 7.69% for long lesions (p = 0.0012), 2.06% vs. 8.75% after 24 months (p = 0.0027) and 4.96% vs. 9.59% after 36 months of follow-up (p = 0.0109). Scaffold thrombosis rates were low.ConclusionsIn long lesions compared to short ones the bioresorbable scaffold Absorb implanted with the proper PSP technique Absorb has significant higher rates of DOCE.The Level of EvidenceIs 3 (non-random sample).

show abstract

Everolimus drug‐eluting stent performance in patients with long coronary lesions: The multicenter Longprime registry

Abstract: In this real-world population, the Xience Prime EES performs extremely well in long lesions, with a very low rate of both MACE and ST.

Cited by 8 publications

References 32 publications

Long-Term Safety and Performance of BioMime™ Morph Sirolimus-Eluting Coronary Stent System for Very Long Coronary Lesions

Long-Term Safety and Performance of BioMime™ Morph Sirolimus-Eluting Coronary Stent System for Very Long Coronary Lesions

Clinical research of drug-coated balloon after rotational atherectomy for severe coronary artery calcification

Clinical results of bioresorbable drug-eluting scaffolds in short and long coronary artery lesions using the PSP technique

Contact Info

Product

Resources

About